Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Udenafil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A known ✓ | O76074 | 20/20 | 0.80 |
| ▸ | PDE2A | O00408 | 1/20 | 0.49 |
| ▸ | PDE9A | O76083 | 1/20 | 0.49 |
| ▸ | PDE4A | P27815 | 1/20 | 0.49 |
| ▸ | PDE6C | P51160 | 1/20 | 0.49 |
| ▸ | PDE1A | P54750 | 1/20 | 0.49 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Udenafil SCHEMBL69463 | 1.00 | PDE5A (0.80) | PDE5APDE2APDE9APDE4APDE6C | |
| SCHEMBL325269 | 0.96 | PDE5A (0.74) | PDE5APDE2APDE9APDE4APDE6C | |
| SCHEMBL3235482 | 0.89 | PDE5A (0.65) | PDE5A | |
| Udenafil SCHEMBL120993 | 0.89 | PDE5A (1.00) | PDE5APDE2APDE9APDE4APDE6C | |
| Udenafil SCHEMBL30452348 | 0.89 | PDE5A (1.00) | PDE5APDE2APDE9APDE4APDE6C | |
| SCHEMBL18416780 | 0.88 | PDE5A (0.69) | PDE5A | |
| SCHEMBL18269491 | 0.88 | PDE5A (0.62) | PDE5A | |
| Udenafil SCHEMBL8054822 | 0.86 | PDE5A (0.94) | PDE5APDE2APDE9APDE4APDE6C | |
| Udenafil SCHEMBL8055433 | 0.86 | PDE5A (0.94) | PDE5APDE2APDE9APDE4APDE6C | |
| Udenafil SCHEMBL8055636 | 0.86 | PDE5A (0.94) | PDE5APDE2APDE9APDE4APDE6C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226084-A9 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
| US-20240226084-A9 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
| WO-2024059335-A1 | METHODS OF TREATING AGE-RELATED AND INHERITED RETINAL DYSFUNCTIONS | UNIVERSITY OF CALIFORNIA - IRVINE (US) | 2024-03-21 | — | — | WO | disclosed |
| US-11857545-B2 | High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-01-02 | — | — | US | disclosed |
| US-11857545-B2 | High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-01-02 | — | — | US | disclosed |
| US-20230372351-A1 | TREATMENT OF ERECTILE DYSFUNCTION AND OTHER INDICATIONS | STRATEGIC SCIENCE & TECHNOLOGIES, LLC (US) | 2023-11-23 | — | — | US | disclosed |
| US-11813256-B2 | High penetration prodrug compositions and pharmaceutical compositon thereof for treatment of pulmonary conditions | PREMIER RESEARCH INTERNATIONAL, LLC | 2023-11-14 | — | — | US | disclosed |
| US-11813256-B2 | High penetration prodrug compositions and pharmaceutical compositon thereof for treatment of pulmonary conditions | PREMIER RESEARCH INTERNATIONAL, LLC | 2023-11-14 | — | — | US | disclosed |
| US-11684624-B2 | Treatment of erectile dysfunction and other indications | STRATEGIC SCIENCE & TECHNOLOGIES, LLC (US) | 2023-06-27 | — | — | US | disclosed |
| US-11684624-B2 | Treatment of erectile dysfunction and other indications | STRATEGIC SCIENCE & TECHNOLOGIES, LLC (US) | 2023-06-27 | — | — | US | disclosed |
| US-20120065165-A1 | COMPOSITIONS AND METHODS OF TREATING ENDOTHELIAL DISORDERS | ARGINETIX, INC (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065165-A1 | COMPOSITIONS AND METHODS OF TREATING ENDOTHELIAL DISORDERS | ARGINETIX, INC (US) | 2012-03-15 | — | — | US | disclosed |
| US-20110306762-A1 | ACID ADDITION SALT OF UDENAFIL, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DONG-A PHARM. CO., LTD. (KR) | 2011-12-15 | — | — | US | disclosed |
| US-20110306762-A1 | ACID ADDITION SALT OF UDENAFIL, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DONG-A PHARM. CO., LTD. (KR) | 2011-12-15 | — | — | US | disclosed |
| US-20110250279-A1 | CONTROLLED-RELEASE COMPOSITION FOR PRODUCING SUSTAINED-RELEASE PREPARATION CONTAINING UDENAFIL | DONG-A PHARM. CO., LTD. (KR) | 2011-10-13 | — | — | US | disclosed |
| EP-2374479-A2 | CONTROLLED-RELEASE COMPOSITION FOR PRODUCING SUSTAINED-RELEASE PREPARATION CONTAINING UDENAFIL | Dong-A Pharm.Co., Ltd. (KR) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010095849-A2 | ACID ADDITION SALT OF UDENAFIL, PREPARATION METHOD THEREOF AND PHAMACEUTICAL COMPOSITION COMPRISING THE SAME | DONG-A PHARM. CO., LTD. (KR) | 2010-08-26 | — | — | WO | disclosed |
| WO-2010062366-A1 | COMPOSITIONS AND METHODS OF TREATING ENDOTHELIAL DISORDERS | ARGINETIX, INC. (US) | 2010-06-03 | — | — | WO | disclosed |
| US-20090318459-A1 | Therapeutic Compositions Comprising a Specific Endothelin Receptor Antagonist and a PDE5 Inhibitor | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-12-24 | — | — | US | disclosed |
| US-20090318459-A1 | Therapeutic Compositions Comprising a Specific Endothelin Receptor Antagonist and a PDE5 Inhibitor | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11684624-B2 | Treatment of erectile dysfunction and other indications | PDE5A, PDE3A, PDE12 | PDE5A 1/4885PDE2A 4/4885PDE9A 6/4885 |
| US-20240226084-A9 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | PDE5A 172/4885PDE2A 308/4885PDE9A 14/4885 |
| US-11813256-B2 | High penetration prodrug compositions and pharmaceutical compositon thereof for treatment of pulmonary conditions | CPA3, PAH, HCAR2 | PDE5A 469/4885PDE2A 579/4885PDE9A 59/4885 |
| US-20110306762-A1 | ACID ADDITION SALT OF UDENAFIL, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | ACSS2, ADSL, OTC | PDE5A 331/4885PDE2A 533/4885PDE9A 140/4885 |
| US-20230372351-A1 | TREATMENT OF ERECTILE DYSFUNCTION AND OTHER INDICATIONS | PDE5A, PDE3A, PDE12 | PDE5A 1/4885PDE2A 4/4885PDE9A 6/4885 |
| US-20090318459-A1 | Therapeutic Compositions Comprising a Specific Endothelin Receptor Antagonist and a PDE5 Inhibitor | PDE5A, EDNRA, PDE3B | PDE5A 1/4885PDE2A 6/4885PDE9A 8/4885 |
| US-20120065165-A1 | COMPOSITIONS AND METHODS OF TREATING ENDOTHELIAL DISORDERS | PDE5A, PDE2A, PDE3A | PDE5A 1/4885PDE2A 2/4885PDE9A 15/4885 |
| US-11857545-B2 | High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions | HRH4, HCAR2, PAH | PDE5A 172/4885PDE2A 308/4885PDE9A 14/4885 |
| US-20110250279-A1 | CONTROLLED-RELEASE COMPOSITION FOR PRODUCING SUSTAINED-RELEASE PREPARATION CONTAINING UDENAFIL | BPHL, SLC10A2, PDE3A | PDE5A 6/4885PDE2A 9/4885PDE9A 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.